Ilsung Pharm Cash Flow Conversion Efficiency

Latest as of June 2026: 0.000x

Ilsung Pharm cash flow conversion efficiency. Based on the latest financial reports, Ilsung Pharm (003120) has a cash flow conversion efficiency ratio of 0.000x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩124.28 Million ≈ $84.22K USD) by net assets (₩379.77 Billion ≈ $257.36 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Ilsung Pharm (2013–2025)

Cash flow conversion efficiency of Ilsung Pharm from 2013 to 2025. This chart illustrates how Ilsung Pharm's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 003120 stock price for real-time trading data and today's change.

Ilsung Pharm Cash Flow Conversion Ratio Explained

Ilsung Pharm cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Ilsung Pharm Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Ilsung Pharm ranked by their cash flow conversion efficiency. Also see 003120 stock market capitalisation for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Themis Medicare Limited NSE:THEMISMED	-0.004x
AVATION PLC LS-01 F:9K0	N/A
Taseco Air Services JSC VN:AST	0.091x
Economic Investment Trust Ltd TO:EVT	0.095x
Dyaco International Inc TW:1598	0.051x
Carbios PA:ALCRB	-0.090x
Rockridge Resources Ltd V:ROCK	0.028x
Sound Financial Bancorp Inc NASDAQ:SFBC	0.018x

Annual Cash Flow Conversion Efficiency for Ilsung Pharm (2013–2025)

The table below shows the annual cash flow conversion efficiency of Ilsung Pharm from 2013 to 2025. Review Ilsung Pharm free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	₩386.34 Billion ≈ $261.82 Million	₩3.88 Billion ≈ $2.63 Million	0.010x	+190.91%
2024-12-31	₩385.13 Billion ≈ $261.00 Million	₩-4.26 Billion ≈ $-2.88 Million	-0.011x	+89.80%
2023-12-31	₩382.75 Billion ≈ $259.39 Million	₩-41.47 Billion ≈ $-28.11 Million	-0.108x	-23.91%
2022-12-31	₩445.57 Billion ≈ $301.95 Million	₩-38.97 Billion ≈ $-26.41 Million	-0.087x	-630.33%
2021-12-31	₩345.91 Billion ≈ $234.42 Million	₩5.70 Billion ≈ $3.87 Million	0.016x	+267.94%
2020-12-31	₩347.48 Billion ≈ $235.48 Million	₩1.56 Billion ≈ $1.06 Million	0.004x	-64.72%
2019-12-31	₩345.49 Billion ≈ $234.13 Million	₩4.39 Billion ≈ $2.97 Million	0.013x	-72.70%
2018-12-31	₩324.34 Billion ≈ $219.80 Million	₩15.09 Billion ≈ $10.23 Million	0.047x	+47.86%
2017-12-31	₩322.83 Billion ≈ $218.77 Million	₩10.16 Billion ≈ $6.88 Million	0.031x	+132.48%
2016-12-31	₩320.10 Billion ≈ $216.93 Million	₩-31.01 Billion ≈ $-21.02 Million	-0.097x	-610.55%
2015-12-31	₩318.34 Billion ≈ $215.74 Million	₩6.04 Billion ≈ $4.09 Million	0.019x	+48.84%
2014-12-31	₩328.68 Billion ≈ $222.74 Million	₩4.19 Billion ≈ $2.84 Million	0.013x	-18.74%
2013-12-31	₩322.74 Billion ≈ $218.72 Million	₩5.06 Billion ≈ $3.43 Million	0.016x	--

About Ilsung Pharm

KO:003120 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$100.47 Million

₩148.25 Billion KRW

Market Cap Rank

#19005 Global

#913 in Korea

Share Price

₩20700.00

Change (1 day)

-2.13%

52-Week Range

₩18300.00 - ₩28300.00

All Time High

₩31693.76